Although methadone (an opioid agonist) and buprenorphine (a partial opioid agonist) have evidence to support their use in treating opioid use disorder, they remain misunderstood and underutilized. In this article, we outline the risks and benefi ts of using these drugs as maintenance therapy in opioid-dependent patients.
F
or a patient struggling with opioid addiction, opioid agonist therapy with methadone or buprenorphine can reduce craving and opioid use and may even save his or her life. But many clinicians are unfamiliar with this evidence-based treatment, 1, 2 which is best started early in the course of addiction. 3 
See related editorial, page 385
This article outlines the pharmacology of these drugs, their clinical uses, and the challenges of using them to treat opioid addiction.
■ DIAGNOSTIC CRITERIA
Opioid addiction, formally known as opioid use disorder, is a pattern of opioid misuse leading to clinically signifi cant impairment in multiple areas of life. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, lists 11 diagnostic criteria, but only 2 need to be present within the past year to make the diagnosis 4 
:
• Taking opioids longer or in higher doses than was intended • A persistent desire or unsuccessful efforts to cut down or control opioid use • Spending a great deal of time obtaining, using, or recovering from using opioids • Craving opioids • Repeatedly failing to fulfi ll obligations at work, school, or home due to opioid use • Continuing to use opioids even though it causes or exacerbates social or interpersonal problems • Giving up or curtailing important social, occupational, or recreational activities because of opioid use • Repeatedly using opioids in situations in which it is physically hazardous Patients being considered for opioid agonist therapy need a comprehensive assessment including a thorough medical history and physical examination, psychiatric evaluation, psychosocial appraisal, and determination of readiness to change.
When methadone and buprenorphine are properly prescribed they confer signifi cant benefi ts, including reduction or elimination of opioid use, reductions in overdose risk, and positive changes in behavior and lifestyle.
• Continuing to use opioids despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance • Tolerance • Withdrawal.
Recent estimates indicate that 2.23 million people in the United States have opioid use disorder (426,000 with heroin and 1.8 million with prescription opioids).
5
Progression from prescription opioids to heroin We have observed that many patients with opioid use disorder start by misusing prescription opioids. Over time, tolerance can develop, which drives patients to use higher and higher doses. 6 As the addiction progresses, a subset of prescription opioid users advances to using heroin, which is typically less expensive and easier to obtain. 7 Most patients start with the intranasal route but eventually inject it intravenously. 6, 7 For many addicts, heroin use has medical consequences such as hepatitis C virus (HCV) and human immunodefi ciency virus (HIV) infection, psychiatric problems such as depression and anxiety, and illegal activities such as theft and sex work. 8 People who use heroin appear to have more severe addiction and a lower socioeconomic status than prescription opioid users. [9] [10] [11] But recently, a growing number of middle class individuals are becoming addicted to heroin. 12 
■ METHADONE
Methadone is a long-acting synthetic opioid that functions as a full agonist on the muopioid receptor. The drug binds, occupies, and stimulates the receptor, preventing withdrawal symptoms and reducing opioid cravings for at least 24 hours. 13 
Adverse effects of methadone
The most common adverse effects include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating.
14 Other adverse effects:
Unintentional overdose. The risk is serious, as a single 30-mg dose can be fatal in people who are opioid-naïve. 13 QTc prolongation, which can lead to torsade de pointes. This risk, which is doserelated, must be taken into consideration in patients who have any cardiac symptoms (eg, syncope, arrhythmia), pathology (familial QT prolongation), or other risk factors for QTc prolongation (eg, hypokalemia, QTc-prolonging medications).
15
Respiratory depression, which can be fatal. This dose-related risk is heightened during the fi rst 4 weeks of treatment if titration is too rapid or if methadone is used in combination with other drugs that cause central nervous system or respiratory depression.
13,14

Starting methadone
To prevent respiratory depression and death related to rapid induction, the general rule is to start methadone at a low daily dose (20-30 mg) depending on the patient's withdrawal symptoms.
14 During this period, patients need to be closely monitored and educated on the perils of concomitant use of central nervous system depressants. 14 In most patients, the dose is titrated up until their withdrawal symptoms and cravings are eliminated, which generally requires 60 to 120 mg daily.
14 Hepatic and renal impairment, pregnancy, and advanced age can alter methadone pharmacokinetics and may therefore necessitate dose adjustment.
■ BUPRENORPHINE
Buprenorphine is an alkaloid thebaine opioid derivative that acts as a partial mu-opioid agonist and a kappa antagonist. 16 Like methadone, buprenorphine is used to manage cravings and withdrawal symptoms. 16 Dosages of 4 to 16 mg (up to 32 mg) per day of buprenorphine are usually required to adequately control opioid cravings.
16
Sublingual and subdermal products Buprenorphine is currently available in the United States in sublingual and subdermal formulations. 16, 17 Sublingual buprenorphine is usually combined with naloxone in a 4:1 ratio to deter intravenous use. 
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one. (Taken orally or sublingually, naloxone is poorly absorbed and has little or no clinical effect.) Buprenorphine-naloxone is available in tablets, a sublingual fi lm strip, and a buccal fi lm strip. Buprenorphine is also available by itself in a sublingual formulation.
The US Food and Drug Administration has approved a buprenorphine subdermal implant, Probuphine. Four rods, about 1 inch long, are placed under the skin in the inner aspect of the upper arm and provide the equivalent of 8 mg of buprenorphine daily for 6 months. 17 However, this method is formulated only for maintenance treatment and cannot be used for induction. Additionally, it is recommended that the implants be surgically removed at the end of 6 months, after which another set of implants can be inserted in the other arm or the patient can switch to sublingual therapy, depending on the clinical situation and patient preference.
17
Generally safer than methadone Buprenorphine works on the same receptor as methadone and therefore has a similar side effect profi le. However, buprenorphine has a ceiling effect, which greatly reduces the risk of fatal respiratory depression. 18 It also does not cause clinically signifi cant QTc prolongation and is preferable in patients who have cardiac risk factors. 18 Another advantage is that buprenorphine has fewer identifi ed medication interactions than methadone. 18 Further, induction of buprenorphine in patients with opioid use disorder has been shown to be safer than methadone. 19 Although buprenorphine has been found to be 6 times safer than methadone with regard to overdose among the general population, 20 it can still cause fatal intoxication if used in combination with central nervous system depressants. 21 Buprenorphine has been also associated with hepatotoxicity, though the risk of newonset liver disease appears to be low. 22 
■ NALTREXONE IS LESS EFFECTIVE THAN METHADONE, BUPRENORPHINE
Besides methadone and buprenorphine, the only other approved option for treating opioid use disorder is the opioid antagonist naltrexone.
Naltrexone has signifi cantly less abuse potential, as it provides no euphoria, but patients do not like it. Even with the long-acting formulation (Vivitrol), naltrexone treatment is signifi cantly less effective than methadone or buprenorphine. [23] [24] [25] Further, although naltrexone is not a controlled substance and so does not face the same scrutiny as the agonist therapies, there are other signifi cant barriers. Additional information on naltrexone is presented in reviews by Modesto-Lowe and Van Kirk 24 and Woody.
■ OBSTACLES TO TREATMENT
People hold confl icting views about opioid agonist therapy. Some believe that "trading one drug for another" is not a legitimate therapeutic strategy, and they may feel ashamed of being on maintenance therapy. 26 Similarly, some argue that the answer to establishing stable abstinence does not lie simply in prescribing medications.
The contrary argument is that these medications, if used appropriately, confer many benefi ts such as reducing the medical and psychosocial sequelae of opioid addiction. 18 In fact, properly treated patients no longer meet the diagnostic criteria of opioid use disorder, and both methadone and buprenorphine are on the World Health Organization's (WHO) list of essential medicines. 27 Despite endorsement by the WHO, the stigma attached to the opioid agonists has been diffi cult to overcome. Patients with opioid use disorder may be viewed with distrust by healthcare providers and often do not feel welcome in healthcare settings or in self-help recovery groups.
28
Barriers to methadone therapy Federal regulations on methadone prescribing and use were established to promote patient safety and decrease diversion, but they may also complicate access to care. 29 They stipulate that to qualify for methadone maintenance, patients need to demonstrate opioid addiction for 1 year, except for pregnant women and those who have been incarcerated in the past 6 months. Patients under the age of 18 must have 2 documented failed treatment episodes as well as approval by a guardian to receive treatment.
Heroin is typically less expensive and easier to obtain than prescription opioids
Inconvenience. Methadone can be prescribed for opioid dependence only by an accredited treatment program. Patients must therefore travel to the clinic and wait to be evaluated on a daily basis for a minimum of 90 days. Only after they demonstrate consistent responsible behavior and negative results on urine testing do they become eligible to take methadone home. 29 If a patient is to travel out of the area during the initial 90 days of treatment, he or she must make arrangements in advance to fi nd a clinic that will provide a "guest dose."
The inconvenience arising from the regulations may deter some patients from seeking methadone therapy. In spite of this, once patients are started on methadone, more of them continue treatment than with buprenorphine. 18 A proposed reason is that methadone is a potent full opioid agonist and therefore relieves withdrawal symptoms and craving more effectively than buprenorphine, which is a partial agonist. 30 Another possible reason is the higher level of supervision afforded by methadone clinics, which require daily contact for at least 90 days.
Safety concerns arise from methadone diversion, as illicit use may have lethal consequences. In the past decade, deaths from methadone overdose have risen signifi cantly, most of them due to respiratory depression or torsade de pointes. 13 However, most cases of diversion and overdose involve methadone that is prescribed for pain by individual practitioners and not from maintenance programs.
13
Advantages of buprenorphine Together, methadone's lethality, stigma, and inconvenience may contribute to patients preferring buprenorphine. 31 The regulations governing buprenorphine's use are less restrictive than those with methadone. For example, patients must have a diagnosis of opioid addiction to be prescribed buprenorphine, but they are not required to carry the diagnosis for a year before treatment. 31 Additionally, they do not need to travel to a federally approved opioid treatment center daily and can receive buprenorphine directly from a physician in an outpatient setting.
Under the Drug Abuse Treatment Act (DATA) of 2000, any physician can apply for a waiver to prescribe and dispense buprenorphine in his or her offi ce. To qualify for an initial waiver, physicians must either obtain certifi cation in the fi elds of addiction medicine or addiction psychiatry or complete an approved 8-hour training session. 32 Each physician starts with a maximum of 30 patients, but can apply to treat up to 100 patients after 1 year and eventually up to 275 patients. Physicians must document every buprenorphine prescription they write and be able to refer patients for counseling. 31 As of February 2017, nurse practitioners and physician assistants can also apply for a DATA 2000 waiver. All waivered providers are subject to unannounced visits from the Drug Enforcement Administration once every 5 years. 32 While there are no federal restrictions on the amount of buprenorphine that can be dispensed, some states and some insurance companies have placed restrictions on dose or length of treatment. 33 Buprenorphine patients can fi ll their prescriptions at any pharmacy and are permitted to bring their medication home, which improves access to care. However, offi ce-based outpatient treatment is not without risk, and preventing buprenorphine diversion remains a challenge.
34
'Lending' buprenorphine is a felony Addicts have illegally used buprenorphine to self-treat opioid withdrawal, craving, and dependence. 35 Its misuse has also been coupled with self-treatment of conditions that include depression and pain. 36 A survey found that 83.7% of patients deem buprenorphine diversion to be appropriate; further, most patients said they consider it unethical to withhold prescribed buprenorphine from individuals showing symptoms of withdrawal. 34 Physicians who prescribe buprenorphine must inform their patients that even "lending" or giving away their medication is a felony.
Prescribing physicians must also be diligent about monitoring for signs of diversion such as inconsistent urine toxicology screens, "lost" medication, and requests for early refi lls or escalating doses.
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Buprenorphine is safer than methadone but can still kill if used with central nervous system depressants MODESTO-LOWE AND COLLEAGUES
■ EVALUATING PATIENTS FOR OPIOID REPLACEMENT THERAPY
In addition to federal regulations, we propose a 4-step approach to evaluate eligibility for opioid replacement therapy based on existing guidelines.
37-39
Step 1: History and physical examination The history should give particular attention to the patient's cardiac, pulmonary, and hepatic status, with consideration of the risks of any medical comorbidities (eg, bacterial endocarditis, HIV and HCV infection) that might infl uence treatment.
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It is also essential to evaluate for any contraindications or drug interactions before prescribing methadone or buprenorphine. Contraindications to buprenorphine use include: • Hypersensitivity to naloxone or buprenorphine • Impaired liver function (due to the risk of inadvertent overdose associated with slowed metabolism). Concurrent use of alcohol or illicit benzodiazepines is a relative contraindication to both methadone and buprenorphine due to the risk of respiratory depression and overdose. 37 Likewise, avoid coprescribing opioid agonists and benzodiazepines whenever possible. Obtain a complete list of current medications and query a prescription-monitoring database to determine whether any controlled substances are currently prescribed. 37 During the physical examination, look for stigmata of intravenous drug use such as track marks or abscesses 37 and document any physical fi ndings consistent with intoxication or withdrawal. Patients must be completely detoxed or in withdrawal before beginning buprenorphine induction; premature induction can precipitate withdrawal. 38 A discussion of pregnant patients with opioid use disorder is beyond the scope of this paper. However, it is incumbent on the prescriber to inquire whether the client is pregnant or intends to become pregnant and what birth control methods are in place.
Step 2: Assess psychiatric status Assessment of the patient's psychiatric status, including an assessment of alcohol and other drug use, will help determine his or her eligibility for opioid agonists. 37 To prepare for the need to manage patients with psychiatrically complex issues, it is helpful to develop relationships with addiction specialists and psychiatrists who are familiar with opioid replacement therapy in your area. This will make it easier to collaborate on patients' care.
Ask all patients directly about suicidal or homicidal ideation. Any patient with active suicidal or homicidal ideation should be assessed for need of immediate hospitalization by a psychiatrist or another qualifi ed mental health professional. Patients with a history of suicidal ideation should be monitored closely by a mental health professional throughout treatment. 37 Many if not most patients with opioid use disorder have concurrent psychiatric disorders, and the interplay between these disorders is complex. 40, 41 Depression, for example, can precede and even precipitate drug use (an observation supporting the "self-medication theory"). 42 If the underlying depressive disorder is not addressed, relapse is nearly inevitable.
It has also been shown that both chronic opioid use and withdrawal can exacerbate aversive emotional states. This escalation of symptoms may result from the pharmacologic effects of opioids or from psychosocial sequelae that can arise from chronic opioid use. 41 In this situation, maintaining abstinence can lead to resolution of depressive symptoms. As depression and opioid use can occur together, successful treatment requires equal attention to both illnesses.
Other common comorbidities in patients with opioid use disorder include posttraumatic stress disorder, attention defi cit hyperactivity disorder, antisocial personality disorder, and concurrent substance abuse disorders. 43 The confl uence of antisocial personality disorder is particularly important, as patients with an- Identify any psychotropic medication that is prescribed and check carefully for drug interactions. This applies especially to methadone, as many psychiatric medications also prolong the QT interval. Moreover, patients may not be forthcoming about the use of psychiatric medication.
Regulations
Find out whether the patient is using any other addictive substances, particularly those that affect the central nervous system, as those who use fentanyl, benzodiazepines, or alcohol are at the highest risk of overdose. 31 Often the best option for those with concurrent substance use disorders is inpatient detoxifi cation followed by residential rehabilitation care. Either buprenorphine or methadone can then be initiated upon return to an outpatient setting.
Step 3: Assess psychosocial status
To what extent do the patient's home environment and support systems promote a drugfree lifestyle? Unfortunately, the psychosocial status of many of these patients is fragile, and they may live in areas where illicit drugs are readily available (which can be urban, suburban, or rural), making it diffi cult to stay substance-free. 38 Generally, lifestyle modifi cations are needed to transform maladaptive behaviors and promote an environment conducive to longterm recovery. Referrals to social services to address housing, vocational needs, and entitlements may be helpful.
39
Step 4: Assess readiness to change According to one model, people go through 5 stages when changing a behavior: precontemplation, contemplation, preparation for action, action, and maintenance. 43 In general, the further along the stages a patient is, the more appropriate he or she is for offi ce-based treatment with buprenorphine. 39 The level of change can be assessed with tools such as Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Use of stage-specifi c strategies may enhance a patient's readiness to cease opioid use. 43 Precontemplation. Those in the precontemplation stage are not ready to think about changing their behavior. 43 They may be unaware of or unwilling to consider the risks associated with their opioid use and resistant to the idea of quitting. Engagement with opioid agonists for individuals in this stage is low and dropout rates are likely high. Thus, the proper approach for "precontemplators" is to help them develop some ambivalence about their opioid use. One tactic is to involve the patient in a discussion of the personal benefi ts and risks of opioid use.
Contemplation. Individuals in the contemplation stage have begun to weigh the costs and benefi ts of opioid use and express ambivalence about it. 44 Because the patient is willing to explore the risks of ongoing use and consider the benefi ts of treatment, the goal in this stage is to elicit a commitment from the individual to seek treatment.
Preparation. The person in this stage moves from thinking about treatment to planning what action to take. 45 As the individual prepares to enter treatment, indecision tends to resurface, as well as self-doubt about his or her ability to change. During this stage, it is important for the provider to spell out goals (abstinence) and strategies (eg, counseling, medication) and enhance a sense of self-effi cacy.
Action and maintenance. Patients in these stages engage in treatment and employ new strategies to abstain from opioid use. Maintaining these behaviors can be a daily struggle. Expressing confi dence in the patient's ability to abstain from use will support his or her progress. Behavioral interventions such as strategic avoidance of triggers and engagement in alternative activities (eg, support groups, exercise, faith-based practices) will help to maintain abstinence.
■ A CHRONIC CONDITION
Opioid use disorder, like many chronic illnesses, requires long-term attention to attain successful patient outcomes. The opioid agonists methadone and buprenorphine are the mainstay of treatment for it, conferring benefi ts such as reducing opioid use and preventing relapse.
Candidates for opioid agonist therapy should undergo a multidisciplinary assessment, including an evaluation on the patient's readiness to change his or her opioid use.
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Patient education should include a discussion of the risks of methadone (eg, respiratory depression, fatal overdose, and QTc prolongation) and buprenorphine (eg hepatotoxicity) and their benefi ts (eg, controlling craving, decreasing the risk of relapse). Patients should also be educated about overdose and diversion.
Despite the diffi culties inherent in treating patients with opioid use disorder, when used appropriately, opioid agonist therapy can be lifesaving for patients struggling with longterm opioid addiction.
■
